

46th Conference of the International Society of Oncology and BioMarkers (ISOBM)

Final Programme

Thursday, October 13, 2022

15:00 - 18:00			ISOBM Board meeting
16:00 - 19:00			Registration
19:00 - 21:00			Welcome reception

Friday, October 14, 2022

8:00 - 9:00			Registration
9:00 - 9:30			Opening Ceremony
	CHAIR	PRESENTER	TITLE
9:30 - 11:00		Session 1	Cancer Biomarkers
	Moro Ricardo, CAN	Moro Ricardo, CAN	Validation of cancer markers with emphasis on screening
	Osredkar Joško, SLO	Duffy Michael Joe, IRL	Personalised treatment for cancer: biomarkers are showing the way
		van Rossum Huub, NED	Laboratory needs for testosterone analysis in prostate cancer
		Osredkar Josko, SLO	Design of a national screening program in Slovenia
11:00 - 11:30			Coffee + Posters
11:30 - 13:00		Session 2	Prostate Cancer
	Kagan Jacob, USA	Ditz Iztok, SLO	Biomarkers for urological cancers
	Kučera Radek, CZE	Kagan Jacob, USA	Validation studies of biomarkers for early detection of aggressive prostate cancer
		Kučera Radek, CZE	The importance of PHI for the prediction of surgical solution or active surveillance of prostate cancer
		Garrido Manuel Antonio, POR	Multi-biomarker evaluation in prostate cancer patients with PSA between 2 and 10 ng/mL
13:00 - 14:00			Lunch
14:00 - 15:00	Barak Vivian, ISR	Kagan Jacob, USA	Keynote: The NCI human tumor atlas
15:00 - 15:30			Coffee + Posters
15:30 - 17:00		Session 3-A	Bladder Cancer
	Ecke Thorsten, GER	Sanchez-Carbajo Marta, ESP	Identifying bladder cancer biomarkers using omics
	Nawroth Roman, GER	Ecke Thorsten, GER	Final results of the german multicenter-study: urinary based rapid tests in comparison to cytology
		Mengual Lourdes, ESP	Are urine biomarkers useful to reduce the number of follow up cystoscopies in bladder cancer patients?
		Roman Nawroth, GER	A novel combination therapy improves effectiveness of the oncolytic adenovirus XVir-N-31 by manipulating E2F/RB dependent replication
15:30 - 17:00		Session 3-B	Gastrointestinal Cancers
	Chechlińska Magdalena, PO	Topolčan Ondrej, CZE	Monitoring a group of markers in liver cancer
	Topolčan Ondrej, CZE	Zick Aviad, ISR	The utility of epigenetic analysis of cfDNA in treating colorectal cancer patients
		Prošenc Zmrzljak Uršula, SLO	Detection of somatic mutations with ddPCR from liquid biopsy of CRC patients
		Šmid Lojze, SLO	Chromogranin in the diagnostic and therapy of neuroendocrine tumors

46th Conference of the International Society of Oncology and BioMarkers (ISOBM)

Final Programme

17:00 - 18:30		Session 4-A	Hematological Cancer
	Mlinarič Raščan Irena, SLO	Podgornik Helena, SLO	Diagnostic algorithms ensure recognition of Ph-like acute lymphoblastic leukemia molecular markers
	Podgornik Helena, SLO	Mlinarič Raščan Irena, SLO	Molecular signatures of venetoclax chronic lymphocytic leukemia resistance
		Lainšček Duško, SLO	An enhanced CRISPR based tool for treating chronic myelogenous leukemia
		Šučurović Sandra, SLO	How to find measurable residual disease markers in hematological malignancies?
Saturday, October 15, 2022			
	CHAIR	PRESENTER	TITLE
8:30 - 10:30		Session 5-A	Breast and Ovarian Cancers
	Nicolini Andrea, ITA	Chechlińska Magdalena, POL	Molecular profiling of ovarian tumor microenvironment
	Schroeder Lars, GER	Schroeder Lars, GER	Immunogenic cell death markers in ovarian cancer
		Nicolini Andrea, ITA	Immunotherapy in addition to first-line hormone therapy for metastatic breast cancer patients
		Škof Erik, SLO	Clinical importance of BRCA mutation in ovarian cancer
		Ferrari Paola, ITA	Molecular mechanisms, biomarkers and emerging therapies for chemotherapy resistant triple negative breast cancer
8:30 - 10:30		Session 5-B	Genetics 1
	Blatnik Ana, SLO	Šetrajčič Dragoš Vita, SLO	The use of RNAseq in discovery of splicing abnormalities
	Pesta Martin, CZE	Strojnik Ksenija, SLO	Germline genetic testing for cancer treatment in prostate and pancreatic cancer patients
		Blatnik Ana, SLO	Genetic analysis of archival tissue when testing for hereditary cancer predispositions
		Škerl Petra, SLO	Methylation status of mismatch repair genes in endometrial and colorectal cancer
		Pesta Martin, CZE	Detection of BRAF mutations by droplet digital PCR in circulating tumor DNA of nonmetastatic melanoma
10:30 - 11:00			Coffee + Posters
11:00 - 13:00		Session 6-A	New Diagnostic Approaches
	Oehr Peter, GER	Oehr Peter, GER	A new diagnostic approach for a more realistic tumor marker follow up during therapy
	Sanchez-Carbayo Marta, ESP	Kinkorova Judita, CZE	Biobanking and big data
		Rok Dežman, SLO	Imaging and clinical biomarkers for the prediction of survival in patients with hepatocellular carcinoma treated with transarterial chemoembolization
		Sanchez-Carbayo Marta, ESP	Methylation profiles for bladder cancer subclassification
11:00 - 13:00		Session 6-B	Liquid Biopsy
	Haselmann Verena, GER	Bronkhorst Abel Jacobus, RSA	Understanding biology of cell-free nucleic acids for clinical decision making
	Bronkhorst Abel, RSA	Haselmann Verena, GER	Implementation of liquid biopsy into patient care
		Marzia del Re, ITA	The application of liquid biopsy to cancer treatment monitoring
		Ungerer Vida, RSA	Cell-free DNA fragmentation patterns in a bone cancer cell line
13:00 - 14:00			Lunch
14:00 - 15:00	Holdenrieder Stefan, GER	Habermann Jens, GER	Keynote: Advancing biomarker research through biobanking in Europe and beyond – from community engagement to cross-country collaborations
15:00 - 15:30			Coffee + Posters

46th Conference of the International Society of Oncology and BioMarkers (ISOBM)

Final Programme

15:30 - 17:00		Session 7-A	Lung Cancer 1
	Holdenrieder Stefan, GER	Holdenrieder Stefan, GER	Tumor markers in lung cancer: outdated or a golden opportunity?
	Van Rossum Huub, NED	Wehnl Birgit, GER	Protein biomarkers revisited in the new therapeutic era
		Van Rossum Huub, NED	Tumor marker algorithms to predict immunotherapy non-responsiveness in NSCLC
15:30 - 17:00		Session 7-B	Novel Anticancer Therapies
	Barak Vivian, ISR	Sever Matjaž, SLO	Clinical implication of CAR T-cell therapy
	Sever Matjaz, SLO	Erwei Song, CHN	Effector immune cell deployment in tumor immunophenotyping and immunotherapies
		Danesi Romano, ITA	Clinical implementation of pharmacogenetics to reduce the risk of toxicity of anticancer drugs
		Kalangi Suresh, IND	Warburg's mitochondrial HK2-VDAC1 complex disruption in cancer drug discovery
17:00 - 18:30		Session 8-A	Lung Cancer 2
	Kučera Radek, CZE	Kučera Radek, CZE	The role of serum tumor markers in follow-up after surgical treatment of malignant lung tumors
	Pesta Martin, CZE	Trape Jaume, ESP	Lung cancer tumour markers in serous effusions and other body fluids
		Trulson Inga, GER	Prognostic biomarkers in advanced lung cancer
		Chechlińska Magdalena, POL	WHO Classification of Tumours Evidence-Gap Map (WCT-EVI MAP)
Sunday, October 16, 2022			
	CHAIR	PRESENTER	TITLE
8:30 - 10:30		Session 9-A	European Group on Tumor Markers (EGTM)
	Duffy Michael Joe, IRL	Duffy Michael Joe, IRL	Circulating tumor DNA as a cancer biomarker: Will it replace standard protein biomarkers?
	Barak Vivian, ISR	Meisl Christina, GER	How a novel web application can help in Urinary Bladder Cancer risk management: The BLUCAB Index®
		Topolcan Ondrej, CZE	Significance tumour biomarkers for tumour aggressiveness
		Barak Vivian, ISR	Early detection of metastases in head and neck cancers
		Session 9-B	German Society for Extracellular Vesicles (GSEV)
8:30 - 10:30	Nazarenko Irina, GER	Nazarenko Irina, GER	Heterogeneous EV populations and their biomarker potential - a comprehensive study
		Tobias Tertel, GER	Single EV analysis by imaging flow cytometry and identification of new biomarkers
		Christoph Preusser, GER	Extracellular vesicles - challenges and pitfalls in the validation of RNA as biomarker
		Basant Thakur, GER	EV-associated DNA as biomarker: potential and challenges
10:30 - 11:00			Coffee + Posters
11:00 - 13:00		Session 10-A	Genetics 2
	Loojenga Leendert, NED	Loojenga Leendert, NED	Genetics in germ cell cancer
	Kowalewska Magdalena, POL	Kowalewska Magdalena, POL	The intratumor bacteria and neutrophilic inflammation in squamous cell vulvar carcinoma
		Zick Aviad, ISR	The utility of epigenetic analysis of cfDNA in treating cancer patients
		Bombač Alenka, SLO	Mutational spectrum in patients with metastatic gastrointestinal stromal tumours

46th Conference of the International Society of Oncology and BioMarkers (ISOBM)

Final Programme

11:00 - 13:00		Session 10-B	Central European Society of Anticancer Drug Research (CESAR) - Novel targets, drug response and resistance: how biomarkers guide translation into practice
	Ritter Christoph, GER	Ritter Christoph, GER	Translational platform for anticancer treatment strategies
	Kloft Charlotte, GER	Bendas Gerd, GER	Heparin in oncology - novel targets and activities for an immuno-oncological perspective
		Kloft Charlotte, GER	Biomarker monitoring and pharmacometric modelling to optimise anticancer therapy
		Holdenrieder Stefan, GER	Nucleic acid and protein biomarkers for therapy guidance
13:00 - 14:00			Lunch
14:00 - 15:00	Barak Vivian, ISR	Zivony Yifat, ISR	Keynote: Scent based multi-cancer early detection
15:00 - 16:30		Session 11-A	BioEndoCar: Omics technology to improve cancer patient care
	Semczuk Andrzej, POL	Lanišnik Rižner Tea, SLO	BioEndoCar: Biomarkers for diagnosis and prognosis of endometrial carcinoma
	Tea Lanišnik Rižner, SLO	Schroeder Christoph, GER	Affinity proteomics for the discovery of novel biomarkers and therapeutic targets
		Tokarz Janina, GER	Metabolomics for deep phenotyping in frequent human diseases
		Fishmann Dmytro, EST	Machine learning in medicine
16:30 - 17:00			Coffee + Posters
17:00 - 18:30		Session 12-A	INSTAND - Quality management issues for established and new markers
	Holdenrieder Stefan, GER	van Rossum Huub, NED	Harmonization status of today's tumor marker assays: a feasibility study using global EQA programs
	van Rossum Huub, NED	Holdenrieder Stefan, GER	Inter-assay comparison of tumor markers in an EQA setting
		Uhlig Carsten, GER	Improving study data quality by automatized extraction, aggregation and evaluation
		Haselmann Verena, GER	Harmonization and standardization of ctDNA testing
17:00 - 18:30		Session 12-B	Novel diagnostic and therapeutic approaches
	Osredkar Joško, SLO	Mirza Muhammad Faran, CHN	DNA nanotechnology for modulating the growth and development of neurons
	Zadnik Vesna, SLO	Šnuderl Matija, SLO	Minimal residual disease monitoring of brain tumors using personalized whole genome cell-free tumor DNA mutational signatures
		Zadnik Vesna, SLO	Public health interventions for reducing cancer burden and improving cancer care
		Stegel Vida, SLO	Genetic testing of ovarian tumour samples at the Institute of Oncology Ljubljana
18:30 - 19:00			ISOBM General Assembly
20:00			Gala dinner

Monday, October 17, 2022

	CHAIR	PRESENTER	TITLE
8:30 - 10:30		Session 13-A	Present and future biomarkers
	Krajc Mateja, SLO	Krajc Mateja, SLO	Cancer genetic screening and personalised cancer risk assessment
	Oehr Peter, GER	Oehr Peter, GER	New established types of ROC-curves and their clinical impact
		Barak Vivian, ISR	sIL-2R- an important immuno-biomarker for cancer
		Karlikova Marie, CZE	Importance of matrix metalloproteinases in tumor diseases

46th Conference of the International Society of Oncology and BioMarkers (ISOBM)

Final Programme

8:30 - 10:30		Session 13-B	ENITEC - How to personalize targeted treatment of gynecological cancer patients
	Colas Ortega Eva, ESP	Romano Andrea, NED	ENITEC Presentation (<i>recorded presentation</i>)
	Perone Emanuele, ITA	Perrone Emanuele, ITA	Implementing the TCGA classification for endometrial cancer: consequences on medical approaches
		Reijnen Casper and Lombaers Marike, NED	Integrating biomarkers into ENDORISK prediction model
		Lanišnik Rižner Tea, SLO	AKR1C and AKR1B enzymes as biomarker candidates of endometrial cancers
		Colas Ortega Eva, ESP	Use of biomarkers in diagnosis and presurgical patient stratification
10:30 - 11:00			Coffee break
11:00 - 12:00	Lanišnik Rižner Tea, SLO	Adamski Jerzy, GER	Keynote: The power of metabolomics in biomarker research
12:00 - 13:00		Osredkar Joško, SLO	Closing Session
13:00			Lunch
14:00 - 16:00			ISOBM Board